Development of a laboratory XANES system for the analysis of metals in tissue for cancer research and chemotherapy drug development

Information

  • Research Project
  • 9559611
  • ApplicationId
    9559611
  • Core Project Number
    R44CA228912
  • Full Project Number
    1R44CA228912-01
  • Serial Number
    228912
  • FOA Number
    PA-17-302
  • Sub Project Id
  • Project Start Date
    4/4/2018 - 6 years ago
  • Project End Date
    9/30/2018 - 5 years ago
  • Program Officer Name
    SUBEDEE, ASHIM
  • Budget Start Date
    4/4/2018 - 6 years ago
  • Budget End Date
    9/30/2018 - 5 years ago
  • Fiscal Year
    2018
  • Support Year
    01
  • Suffix
  • Award Notice Date
    4/4/2018 - 6 years ago
Organizations

Development of a laboratory XANES system for the analysis of metals in tissue for cancer research and chemotherapy drug development

Project Summary/Abstract Due to recent major advances in understanding platinum chemotherapy drugs, which are used to treat an estimated 50-70% of cancer patients, a new frontier of metal-based anti-cancer drugs is emerging. Many promising novel metal-based drugs (e.g. Ru, Co, Au, Sn, etc.) and several new formulations of platinum prodrugs are now being investigated as replacements for conventional platinum therapies. These alternatives hold significant potential for overcoming the well-known disadvantages of current Pt-based chemotherapy, including the development of patient resistance and toxicity to non-tumorous tissue, including hair fall-out and damage to vital organs such as the kidney and brain. X-ray absorption near edge spectroscopy (XANES) is a powerful chemical analysis technique used to investigate the local atomic structure of these drugs. The electron structure of these new metal-based chemotherapy drugs is critical to their performance, including: intracellular activation in tumorous cells, transportation to the tumor, activity, and lifetime of the drug. However, these drugs exist in low concentrations in biological tissue and currently, XANES analysis requires researchers to travel to synchrotron light sources, which generate intense beams of x-rays but of which there are just a handful, as they cost $1B to build and ~$100M/year to operate. Synchrotron XANES systems are often extremely oversubscribed, with up to a 6-9-month application process and some beamlines limiting groups to a single run per year, all of which significantly limit access and the rate of research progress. We propose to develop a laboratory XANES system that utilizes a combination of breakthrough innovations to bring access to the capabilities of synchrotron-based XANES to laboratories worldwide. The system is expected to critically enable research in novel metal-based anti-cancer drugs, in addition to emerging research on the role of trace metal chemistry in pathologies including cancer. The proposed Phase I 6-month project is a proof-of-principle demonstration of the advantages stemming from the x-ray optic and geometry in a breadboard prototype. The proposed Phase II 24-month project is to develop a complete prototype.

IC Name
NATIONAL CANCER INSTITUTE
  • Activity
    R44
  • Administering IC
    CA
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
    224989
  • Sub Project Total Cost
  • ARRA Funded
    False
  • CFDA Code
    394
  • Ed Inst. Type
  • Funding ICs
    NCI:224989\
  • Funding Mechanism
    SBIR-STTR RPGs
  • Study Section
    ZRG1
  • Study Section Name
    Special Emphasis Panel
  • Organization Name
    SIGRAY, INC.
  • Organization Department
  • Organization DUNS
    079183051
  • Organization City
    CONCORD
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    945205345
  • Organization District
    UNITED STATES